心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

《中国肺动脉高压诊断与治疗指南（2021版）》解读——结缔组织病相关肺动脉高压

2021-12-01 中国医学科学院北京协和医学院 中国实用内科杂志

肺动脉高压

肺动脉高压(PH)是结缔组织病(CTD)的严重并发症之一,其中,以第一大类PH,即动脉性肺动脉高压(PAH)最为常见。因起病隐匿、临床表现缺乏特异性、早期诊断困难、治疗效果不佳,PAH已成为CTD患者

中文标题：

《中国肺动脉高压诊断与治疗指南（2021版）》解读——结缔组织病相关肺动脉高压

发布机构：

中国医学科学院北京协和医学院

发布日期：

2021-12-01

简要介绍：

肺动脉高压(PH)是结缔组织病(CTD)的严重并发症之一,其中,以第一大类PH,即动脉性肺动脉高压(PAH)最为常见。因起病隐匿、临床表现缺乏特异性、早期诊断困难、治疗效果不佳,PAH已成为CTD患者死亡的重要因素之一。文章针对中华医学会呼吸病学分会肺栓塞与肺血管病学组发布的《中国肺动脉高压诊断与治疗指南(2021版)》中CTD相关PAH部分的推荐意见进行解读,提倡CTD相关PAH的早期筛查、精确诊断、全面评估和精准治疗,以期改善CTD相关PAH患者的长期预后,提高患者生活质量。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=《中国肺动脉高压诊断与治疗指南（2021版）》解读——结缔组织病相关肺动脉高压.pdf)] GetToolGuiderByIdResponse(projectId=1, id=bfe2e1c002355527, title=《中国肺动脉高压诊断与治疗指南（2021版）》解读——结缔组织病相关肺动脉高压, enTitle=, guiderFrom=中国实用内科杂志, authorId=0, author=, summary=肺动脉高压(PH)是结缔组织病(CTD)的严重并发症之一,其中,以第一大类PH,即动脉性肺动脉高压(PAH)最为常见。因起病隐匿、临床表现缺乏特异性、早期诊断困难、治疗效果不佳,PAH已成为CTD患者, cover=https://img.medsci.cn/2022213/1644721949030_5579292.jpg, journalId=0, articlesId=null, associationId=2420, associationName=中国医学科学院北京协和医学院, associationIntro=中国医学科学院北京协和医学院, copyright=0, guiderPublishedTime=Wed Dec 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">肺动脉高压(PH)是结缔组织病(CTD)的严重并发症之一,其中,以第一大类PH,即动脉性肺动脉高压(PAH)最为常见。因起病隐匿、临床表现缺乏特异性、早期诊断困难、治疗效果不佳,PAH已成为CTD患者死亡的重要因素之一。文章针对中华医学会呼吸病学分会肺栓塞与肺血管病学组发布的《中国肺动脉高压诊断与治疗指南(2021版)》中CTD相关PAH部分的推荐意见进行解读,提倡CTD相关PAH的早期筛查、精确诊断、全面评估和精准治疗,以期改善CTD相关PAH患者的长期预后,提高患者生活质量。&nbsp;</span></p>, tagList=[TagDto(tagId=1179, tagName=肺动脉高压)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3929, appHits=221, showAppHits=0, pcHits=572, showPcHits=3707, likes=1, shares=44, comments=9, approvalStatus=1, publishedTime=Mon Feb 14 15:10:00 CST 2022, publishedTimeString=2021-12-01, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Sun Feb 13 11:15:52 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 16:47:10 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《中国肺动脉高压诊断与治疗指南（2021版）》解读——结缔组织病相关肺动脉高压.pdf)])
《中国肺动脉高压诊断与治疗指南（2021版）》解读——结缔组织病相关肺动脉高压.pdf
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207628, encodeId=ebe4120e62811, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62342839718, createdName=188927378, createdTime=Thu Mar 31 19:00:46 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200036, encodeId=d9b71200036cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210810/6ce3b236b9be400693c90d23bb389365/40a17e61634f490a940e13fb657551c5.jpg, createdBy=270e5568770, createdName=WWYyyyu, createdTime=Sun Mar 06 21:45:47 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198647, encodeId=37d8119864ebd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ef5427595, createdName=大芳, createdTime=Wed Mar 02 10:52:53 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196562, encodeId=21d91196562e7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae742540399, createdName=1251df21m40暂无昵称, createdTime=Wed Feb 23 21:32:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195441, encodeId=1bdd11954415a, content=很好，知识面广，值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Sun Feb 20 21:24:07 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
    2022-03-31 188927378

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207628, encodeId=ebe4120e62811, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62342839718, createdName=188927378, createdTime=Thu Mar 31 19:00:46 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200036, encodeId=d9b71200036cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210810/6ce3b236b9be400693c90d23bb389365/40a17e61634f490a940e13fb657551c5.jpg, createdBy=270e5568770, createdName=WWYyyyu, createdTime=Sun Mar 06 21:45:47 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198647, encodeId=37d8119864ebd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ef5427595, createdName=大芳, createdTime=Wed Mar 02 10:52:53 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196562, encodeId=21d91196562e7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae742540399, createdName=1251df21m40暂无昵称, createdTime=Wed Feb 23 21:32:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195441, encodeId=1bdd11954415a, content=很好，知识面广，值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Sun Feb 20 21:24:07 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
    2022-03-06 WWYyyyu

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1207628, encodeId=ebe4120e62811, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62342839718, createdName=188927378, createdTime=Thu Mar 31 19:00:46 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200036, encodeId=d9b71200036cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210810/6ce3b236b9be400693c90d23bb389365/40a17e61634f490a940e13fb657551c5.jpg, createdBy=270e5568770, createdName=WWYyyyu, createdTime=Sun Mar 06 21:45:47 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198647, encodeId=37d8119864ebd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ef5427595, createdName=大芳, createdTime=Wed Mar 02 10:52:53 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196562, encodeId=21d91196562e7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae742540399, createdName=1251df21m40暂无昵称, createdTime=Wed Feb 23 21:32:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195441, encodeId=1bdd11954415a, content=很好，知识面广，值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Sun Feb 20 21:24:07 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
    2022-03-02 大芳

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1207628, encodeId=ebe4120e62811, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62342839718, createdName=188927378, createdTime=Thu Mar 31 19:00:46 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200036, encodeId=d9b71200036cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210810/6ce3b236b9be400693c90d23bb389365/40a17e61634f490a940e13fb657551c5.jpg, createdBy=270e5568770, createdName=WWYyyyu, createdTime=Sun Mar 06 21:45:47 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198647, encodeId=37d8119864ebd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ef5427595, createdName=大芳, createdTime=Wed Mar 02 10:52:53 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196562, encodeId=21d91196562e7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae742540399, createdName=1251df21m40暂无昵称, createdTime=Wed Feb 23 21:32:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195441, encodeId=1bdd11954415a, content=很好，知识面广，值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Sun Feb 20 21:24:07 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
    2022-02-23 1251df21m40暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1207628, encodeId=ebe4120e62811, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62342839718, createdName=188927378, createdTime=Thu Mar 31 19:00:46 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200036, encodeId=d9b71200036cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210810/6ce3b236b9be400693c90d23bb389365/40a17e61634f490a940e13fb657551c5.jpg, createdBy=270e5568770, createdName=WWYyyyu, createdTime=Sun Mar 06 21:45:47 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198647, encodeId=37d8119864ebd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ef5427595, createdName=大芳, createdTime=Wed Mar 02 10:52:53 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196562, encodeId=21d91196562e7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae742540399, createdName=1251df21m40暂无昵称, createdTime=Wed Feb 23 21:32:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195441, encodeId=1bdd11954415a, content=很好，知识面广，值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Sun Feb 20 21:24:07 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
    2022-02-20 ms3000000637975859

    很好，知识面广，值得学习

    0

相关指南

《中国肺动脉高压诊断与治疗指南（2021版）》解读——聚焦先天性心脏病相关肺动脉高压

首都医科大学附属北京安贞医院小儿心脏中心 · 2021-10-01

治疗儿科动脉性肺动脉高压药物临床试验技术指导原则

国家药品监督管理局药品审评中心（CDE） · 2022-01-12

治疗动脉性肺动脉高压药物临床试验技术指导原则

国家药品监督管理局药品审评中心（CDE） · 2022-01-12

《中国肺动脉高压诊断与治疗指南（2021版）》解读——肺部疾病和（或）低氧所致肺动脉高压

暂未更新 · 2022-01-01

2020 KSC/KATRD指南：肺动脉高压的诊断和治疗（概要）

韩国心脏学会(KSC,Korean Society of Cardiology) · 2021-06-04

中国肺动脉高压诊断与治疗指南(2021版)

中华医学会呼吸病学分会 肺栓塞与肺血管病学组 · 2021-01-05